Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation

Ruchit R. Shah, Ajay Pillai, Pascha Emmons Schafer, David Meggo, Tom McElderry, Vance Plumb, Takumi Yamada, Vineet Kumar, Harish Doppalapudi, Alicia Gunter, Emily Pentecost, William R. Maddox

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Thromboembolic cerebrovascular accident remains a rare but potentially devastating complication of catheter-based atrial fibrillation (AF) ablation. Uninterrupted oral anticoagulant therapy with warfarin has become the standard of care when performing catheter-based AF ablation. Compared with warfarin, apixaban, a factor Xa inhibitor, has been shown to reduce the risk of stroke and major bleeding in nonvalvular AF. With an increase in apixaban use for stroke prophylaxis in patients with AF, there is an increased interest in the safety and efficacy of uninterrupted apixaban therapy during AF ablation. We compared the safety and efficacy of uninterrupted OA therapy with either warfarin or apixaban in all patients who underwent catheter-based AF ablation at the University of Alabama at Birmingham and at Augusta University Medical Center from January 7, 2013, to February 25, 2016. All patients underwent a transesophageal echocardiogram on the day of their ablation to assess for the presence of intracardiac thrombi. All complications were identified and classified as bleeding, thromboembolic events, or other. A total of 627 patients were analyzed as described earlier. There were 310 patients in the warfarin group and 317 patients in the apixaban group. There were 8 complications in the warfarin group and 5 complications in the apixaban group (p = 0.38). There were no thromboembolic complications in either group. In conclusion, the use of apixaban is as safe and effective as warfarin for uninterrupted OA therapy during catheter-based ablation of AF.

Original languageEnglish (US)
Pages (from-to)404-407
Number of pages4
JournalAmerican Journal of Cardiology
Volume120
Issue number3
DOIs
StatePublished - Aug 1 2017

Fingerprint

Warfarin
Atrial Fibrillation
Safety
Catheters
Stroke
Therapeutics
Hemorrhage
Catheter Ablation
Standard of Care
apixaban
Anticoagulants
Thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation. / Shah, Ruchit R.; Pillai, Ajay; Schafer, Pascha Emmons; Meggo, David; McElderry, Tom; Plumb, Vance; Yamada, Takumi; Kumar, Vineet; Doppalapudi, Harish; Gunter, Alicia; Pentecost, Emily; Maddox, William R.

In: American Journal of Cardiology, Vol. 120, No. 3, 01.08.2017, p. 404-407.

Research output: Contribution to journalArticle

Shah, RR, Pillai, A, Schafer, PE, Meggo, D, McElderry, T, Plumb, V, Yamada, T, Kumar, V, Doppalapudi, H, Gunter, A, Pentecost, E & Maddox, WR 2017, 'Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation', American Journal of Cardiology, vol. 120, no. 3, pp. 404-407. https://doi.org/10.1016/j.amjcard.2017.04.041
Shah, Ruchit R. ; Pillai, Ajay ; Schafer, Pascha Emmons ; Meggo, David ; McElderry, Tom ; Plumb, Vance ; Yamada, Takumi ; Kumar, Vineet ; Doppalapudi, Harish ; Gunter, Alicia ; Pentecost, Emily ; Maddox, William R. / Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation. In: American Journal of Cardiology. 2017 ; Vol. 120, No. 3. pp. 404-407.
@article{0fd537f041eb4099881e8857d14dd597,
title = "Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation",
abstract = "Thromboembolic cerebrovascular accident remains a rare but potentially devastating complication of catheter-based atrial fibrillation (AF) ablation. Uninterrupted oral anticoagulant therapy with warfarin has become the standard of care when performing catheter-based AF ablation. Compared with warfarin, apixaban, a factor Xa inhibitor, has been shown to reduce the risk of stroke and major bleeding in nonvalvular AF. With an increase in apixaban use for stroke prophylaxis in patients with AF, there is an increased interest in the safety and efficacy of uninterrupted apixaban therapy during AF ablation. We compared the safety and efficacy of uninterrupted OA therapy with either warfarin or apixaban in all patients who underwent catheter-based AF ablation at the University of Alabama at Birmingham and at Augusta University Medical Center from January 7, 2013, to February 25, 2016. All patients underwent a transesophageal echocardiogram on the day of their ablation to assess for the presence of intracardiac thrombi. All complications were identified and classified as bleeding, thromboembolic events, or other. A total of 627 patients were analyzed as described earlier. There were 310 patients in the warfarin group and 317 patients in the apixaban group. There were 8 complications in the warfarin group and 5 complications in the apixaban group (p = 0.38). There were no thromboembolic complications in either group. In conclusion, the use of apixaban is as safe and effective as warfarin for uninterrupted OA therapy during catheter-based ablation of AF.",
author = "Shah, {Ruchit R.} and Ajay Pillai and Schafer, {Pascha Emmons} and David Meggo and Tom McElderry and Vance Plumb and Takumi Yamada and Vineet Kumar and Harish Doppalapudi and Alicia Gunter and Emily Pentecost and Maddox, {William R.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.amjcard.2017.04.041",
language = "English (US)",
volume = "120",
pages = "404--407",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation

AU - Shah, Ruchit R.

AU - Pillai, Ajay

AU - Schafer, Pascha Emmons

AU - Meggo, David

AU - McElderry, Tom

AU - Plumb, Vance

AU - Yamada, Takumi

AU - Kumar, Vineet

AU - Doppalapudi, Harish

AU - Gunter, Alicia

AU - Pentecost, Emily

AU - Maddox, William R.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Thromboembolic cerebrovascular accident remains a rare but potentially devastating complication of catheter-based atrial fibrillation (AF) ablation. Uninterrupted oral anticoagulant therapy with warfarin has become the standard of care when performing catheter-based AF ablation. Compared with warfarin, apixaban, a factor Xa inhibitor, has been shown to reduce the risk of stroke and major bleeding in nonvalvular AF. With an increase in apixaban use for stroke prophylaxis in patients with AF, there is an increased interest in the safety and efficacy of uninterrupted apixaban therapy during AF ablation. We compared the safety and efficacy of uninterrupted OA therapy with either warfarin or apixaban in all patients who underwent catheter-based AF ablation at the University of Alabama at Birmingham and at Augusta University Medical Center from January 7, 2013, to February 25, 2016. All patients underwent a transesophageal echocardiogram on the day of their ablation to assess for the presence of intracardiac thrombi. All complications were identified and classified as bleeding, thromboembolic events, or other. A total of 627 patients were analyzed as described earlier. There were 310 patients in the warfarin group and 317 patients in the apixaban group. There were 8 complications in the warfarin group and 5 complications in the apixaban group (p = 0.38). There were no thromboembolic complications in either group. In conclusion, the use of apixaban is as safe and effective as warfarin for uninterrupted OA therapy during catheter-based ablation of AF.

AB - Thromboembolic cerebrovascular accident remains a rare but potentially devastating complication of catheter-based atrial fibrillation (AF) ablation. Uninterrupted oral anticoagulant therapy with warfarin has become the standard of care when performing catheter-based AF ablation. Compared with warfarin, apixaban, a factor Xa inhibitor, has been shown to reduce the risk of stroke and major bleeding in nonvalvular AF. With an increase in apixaban use for stroke prophylaxis in patients with AF, there is an increased interest in the safety and efficacy of uninterrupted apixaban therapy during AF ablation. We compared the safety and efficacy of uninterrupted OA therapy with either warfarin or apixaban in all patients who underwent catheter-based AF ablation at the University of Alabama at Birmingham and at Augusta University Medical Center from January 7, 2013, to February 25, 2016. All patients underwent a transesophageal echocardiogram on the day of their ablation to assess for the presence of intracardiac thrombi. All complications were identified and classified as bleeding, thromboembolic events, or other. A total of 627 patients were analyzed as described earlier. There were 310 patients in the warfarin group and 317 patients in the apixaban group. There were 8 complications in the warfarin group and 5 complications in the apixaban group (p = 0.38). There were no thromboembolic complications in either group. In conclusion, the use of apixaban is as safe and effective as warfarin for uninterrupted OA therapy during catheter-based ablation of AF.

UR - http://www.scopus.com/inward/record.url?scp=85020190204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020190204&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2017.04.041

DO - 10.1016/j.amjcard.2017.04.041

M3 - Article

VL - 120

SP - 404

EP - 407

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 3

ER -